| News

Novartis subsidiary Alcon is now an independent company

09.04.2019

Novartis completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution. The Basel pharma giant reports it is now positioned for sustained growth and announced the launch of potential blockbusters.

Basel bridge Novartis Campus Rhine River Innovation Business

The successful execution of the spin-off of Alcon allows Novartis to now fully focus on its medicines, the Basel pharma company reported in a press release. This will also lead to higher group margins. In particular, it plans to improve the Innovative Medicines divisions, in which Novartis is aiming for core margins into the mid-30s by 2022. After granting shareholders a dividend of 2.85 Swiss francs per share for 2019, it plans to pay a “strong and growing annual dividend” in future. The share buyback of up to US$ 5 billion announced in June 2018 is expected to be completed this year.

For achieving sustained growth going forward, Novartis is looking to launch ten potential blockbusters in the next two years.  A blockbuster is a drug with annual sales of at least US$ 1 billion. The company also has an additional 20 potential blockbusters on the horizon.

Shares in the spin-off eye specialist Alcon are now listed on the SIX Swiss Exchange and on the New York Stock Exchange. The company was valued at around US$ 27 billion on flotation. “This is an incredibly exciting day for both Novartis and Alcon,” said CEO Vas Narasimhan in the Novartis press release. Alcon has achieved continuous growth and gone public from a position of great strength. “At Novartis, we continue to reimagine ourselves as a leading medicines company powered by breakthrough medicines, data science and advanced therapy platforms.”

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Botanikind settles in Basel
Basel Area Business & Innovation, Innovation, Invest

Botanikind settles in Basel

The internationally active Swiss company Botanikind has settled in Basel and established Botanikind AG there. It provides natural ingredients for...

Read More
Kinarus secures capital commitment of 57 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

Kinarus secures capital commitment of 57 million Swiss francs

The biopharmaceutical company Kinarus has signed a capital commitment of up to 57 million Swiss francs with the investment group...

Read More
Biotech startups from the Basel Area confirm leading position
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Biotech startups from the Basel Area confirm leading position

As part of the Top 100 Swiss Startup Awards 2021, the most promising startups in Switzerland are honored. These also...

Read More
T3 Pharma wins Swiss Economic Award
Basel Area Business & Innovation, Innovation, Invest

T3 Pharma wins Swiss Economic Award

T3 Pharma has won the Swiss Economic Award 2021. Switzerland’s most prestigious young entrepreneur prize is awarded by the Swiss...

Read More
Worg selects Basel Area for European headquarters
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Worg selects Basel Area for European headquarters

Worg Pharmaceuticals has opted to establish its European headquarters at the site Allschwil of the Switzerland Innovation Park Basel Area....

Read More
ten23 health settles in Basel
Basel Area Business & Innovation, Innovation, Invest

ten23 health settles in Basel

The life sciences cluster Rosental Mitte located in Basel is home to a new, globally active company called ten23 health....

Read More
Lumineo installs translucent concrete wall for Vinci
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Lumineo installs translucent concrete wall for Vinci

The global construction and energy group Vinci engaged the jurassic Lumineo Group to design a wall made from translucent concrete...

Read More
Roivant invests 200 million dollars in Immunovant
Basel Area Business & Innovation, Innovation, Invest

Roivant invests 200 million dollars in Immunovant

The Basel-based Roivant Group has invested a total of 200 million dollars in the US biopharmaceutical company Immunovant. This investment...

Read More
Lyfegen collaborating with Johnson & Johnson
Basel Area Business & Innovation, Innovation, Invest

Lyfegen collaborating with Johnson & Johnson

The Basel-based startup Lyfegen has developed a platform for value-based healthcare. This should provide improved outcomes for patients and result...

Read More
Bottmedical enters the market with innovative braces
Basel Area Business & Innovation, Innovation, Invest

Bottmedical enters the market with innovative braces

The Basel-based startup Bottmedical has developed clear braces made from bio-based polymers. After closing a successful financing round, the company...

Read More
1 2 3 29

Do you have a question? We'd like to hear from you.